InvestorsHub Logo
Followers 6
Posts 108
Boards Moderated 0
Alias Born 08/30/2013

Re: luvgrowth post# 2889

Friday, 10/25/2013 1:29:05 PM

Friday, October 25, 2013 1:29:05 PM

Post# of 108192
Advaxis is a development stage biotech with no revenues. As per their management (take a look at latest company presentation on their site), the company is in talks to finalize definitive agreements.

One is to license ADXS-HPV for commercialization in Asia (except India) with Yenson. The other is licensing deal with animal health division of major pharmaceutical company for ADXS-cHER2. These have the potential to bring in some funding.

Upside and downside really depend on the outcomes of several upcoming catalysts. Comparing them to others in the field like INO ($400M cap) and IMUC ($150M), you see how undervalued Advaxis is with a sub $50M cap
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News